M&A trends in Pharma: Takeover activity in the last two and a half years

M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as favorable as desired. Current trends show the mega-mergers of the past are now a long gone strategy, as now companies are seeking to buy smaller companies for a smaller fee.

Pharmaceutical Company Outlook to 2013

PharmaVitae universe Rx sales are forecast to expand at a 2007-13 CAGR of 2.4%, down 7.6 percentage points from 2001-07. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Strategic issues - Potential remains uncertain

Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.

Trends in Pharmaceutical Portfolio Management - Strategies to maintain profitability despite adversity

With growing competition, Pharma companies are under increased pressure to deliver additional value for key stakeholders through their portfolios. Companies with comprehensive portfolios offering more to physicians, patients, payers and pharmacists will have the competitive edge.

Licensing to Win

As stakes get higher, and agreements get more challenging, what will it take for companies to win at licensing?

In an industry some accuse of stagnating, the ongoing rapid growth of licensing is a shining example of continuing clinical and business innovation and leadership. Licensing is already key to pharma’s success; last year, more than 350 deals with an announced value of over $25 billion helped make licensing responsible for more than half of major companies’ new product launches, and much of their pipelines.

Download  the full 28 pages report at Farmavita.Net - Download 

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

PHARMACEUTICALS AND BIOTECHNOLOGY IN CROATIA
Attractive Investment Opportunities

The pharmaceutical industry has a long tradition in Croatia and ‘know-how', promising successful future development of this and related industries. The most important pharmaceutical companies in Croatia are Pliva, Belupo, and Jadran Galenski Laboratorij. The pharmaceutical industry represents 4% of the total manufacturing industry employing 1.7% of the total employment in manufacturing in Croatia.

Complete  report (80 pages) is available for FREE downloat at Farmavta.Net Downloads Section.

Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000–2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.